AR and prostate carcinoma: The androgen-dependent prostate cancer cell line LNCaP is sensitive to AR inhibitors such as apalutamide (Figure 1—figure supplement 1A) and enzalutamide (Figure 1—figure supplement 1B), making it a model system well-suited for the unbiased discovery of novel regulators of AR inhibitor sensitivity in prostate cancer cells.